Candel Therapeutics to Host Virtual R&D Day on December 6, 2022
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409…
New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409…
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour…
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour…
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD…
INmune Bio, a leader in novel therapies and innovative trial design for AD participates in 15th CTAD…
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience…
Former Roche executive Amy Levin, RAC, brings more than 20 years of regulatory affairs experience…
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) — Applied Genetic Technologies Corporation…
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via…
Peer-reviewed data indicates that food significantly decreases and delays the absorption of diazepam dosed via…
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano,…
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano,…
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical…
Tel-Aviv, Nov. 29, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage pharmaceutical…
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including…
Transaction proceeds, together with cash on-hand, expected to fund operations through late 2023/early 2024, including…
Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace CARSON…
Company is Opting to Increase Study Size to 400 due to Fast Enrollment Pace CARSON…
Disrupting Erectile Dysfunction (ED) Market With Oral Spray Aspargo Laboratories, Inc. to leverage Laboratorio SIDUS’…